序贯BTKi与维奈克拉治疗套细胞淋巴瘤的耐药机制及克隆演化
本研究采用低覆盖度全基因组测序(lcWGS)分析序贯BTKi与维奈克拉治疗的双耐药套细胞淋巴瘤(MCL)患者的拷贝数图谱与克隆演化。治疗后样本的拷贝数改变(CNA)较治疗前显著增多(p=0.039)。早期BTKi进展者CNA涉及NOTCH1、TRAF2、BIRC2、BIRC3和ATM编码区;3例维奈克拉耐药者中2例检出9p21.3缺失,MCL2患者还获得SMARCA4-del(19)和DLC1-del(8)。
要点
- 系统治疗后MCL样本CNA较治疗前显著增多(p=0.039)
- 早期BTKi进展者CNA累及NOTCH1、TRAF2、BIRC2、BIRC3和ATM
- 3例维奈克拉耐药者中2例检出9p21.3缺失
核心结论
- lcWGS揭示序贯BTKi与维奈克拉双耐药MCL患者存在新的原发性和获得性耐药机制。
研究设计与样本
- 对序贯BTKi与维奈克拉治疗的双耐药MCL患者样本行低覆盖度全基因组测序(lcWGS)分析拷贝数图谱与克隆演化。
主要发现
- 系统治疗后样本的CNA较治疗前样本增多(p=0.039;Wilcoxon检验)。
- 早期BTKi进展者CNA涉及NOTCH1、TRAF2、BIRC2、BIRC3和ATM编码区所在细胞遗传带。
- 3例维奈克拉耐药患者中2例检出染色体9p21.3缺失。
- MCL2患者病程中始终存在9p21.3缺失,复发时获得SMARCA4-del(19)(p13.3-q13.11)和DLC1-del(8)(p23.2-q11.1)。
临床怎么用
- 对BTKi与维奈克拉双耐药MCL患者可考虑lcWGS检测CNA以识别耐药相关改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments. Since patients relapsing on targeted treatment experience poor clinical outcomes, understanding the genetic foundation of resistance mechanisms in MCL is essential. In this study, we aimed to scrutinize the copy number profile and clonal dynamics of double-resistant MCL patients treated sequentially with Bruton's tyrosine kinase inhibitor (BTKi) and venetoclax using low-coverage whole genome sequencing (lcWGS). Samples obtained after systemic therapy showed more copy number alterations (CNAs) (p = 0.039; Wilcoxon) compared to samples collected before treatment initiation. Patients showing early progression on BTKi demonstrated CNAs affecting cytobands encompassing the coding regions of NOTCH1, TRAF2, BIRC2, BIRC3, and ATM. A deletion in chromosome 9p21.3 was identified in two out of three venetoclax-resistant patients. For patient MCL2, progressing on ibrutinib but showing venetoclax resistance, a 9p21.3 deletion was found throughout the disease course, with acquired SMARCA4-del(19)(p13.3-q13.11) and DLC1-del(8)(p23.2-q11.1) observed at relapse, highlighting their role in disease progression and therapy resistance. Using lcWGS, an innovative genome-wide approach, this study revealed novel putative primary and acquired resistance mechanisms in BTKi and venetoclax double-resistant MCL patients. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
引用
- László T, Pinczés LI, Bátai B, et al. Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy. J Pathol. 2025. PMID: 40371810. doi:10.1002/path.6434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。